![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 21, 2014 2:06:40 PM
IMO both presentations, ASGCT and ASCO, can be for the Melanoma Clinical Trials P1/P2 with a big difference though as to what would be presented at ASGCT vs ASCO
At ASGCT, Dr. Heller would present in a summary all of the existing Public information ALREADY DISCLOSED by $ONCS and describe the Gene/Cell therapy theory as related to the Protein IL-12 and the EP enhancement as creation of the induced immunogenicity of the Melanoma cancer tumor and the role of (1) EP and (2) IL-12.
At ASCO, Dr. Daud, as the $ONCS principal investigator, or Dr. Pierce as $ONCS CMO, would present in a summary all of the new Non-Public latest Oncology information NEVER DISCLOSED by $ONCS TLD for the P1 and P2 latest historical statistical data as of Jan 2014 for Peer Review and Judgement evaluation.
This type of two different presentations regarding the same therapy for the same disease has been done before by Pharmas within a short time span of a few weeks or a few months apart. The first a general summary of past public information and the 2nd Peer Review TLD new data. The 2nd Peer Review can be live presentation or submittal to a Peer Review Journal.
JMHO
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM